144060-62-8

Basic information

• Product Name: Febuxostat Impurity 8
• Synonyms: Febuxostat Impurity 8;Febuxostat ImpurityF;Febuxostat Impurity L;FeBuxostat Impurity 29;Febuxostat Impurity Z19
• CAS NO: 144060-62-8
• Molecular Formula: C₁₆H₁₇NO₄S
• Molecular Weight: 319.37548
• Mol File: 144060-62-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 535.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.268±0.06 g/cm3(Predicted)
• PKA: 1.22±0.37(Predicted)
• CAS DataBase Reference: Febuxostat Impurity 8(CAS DataBase Reference)
• NIST Chemistry Reference: Febuxostat Impurity 8(144060-62-8)
• EPA Substance Registry System: Febuxostat Impurity 8(144060-62-8)

Safety Data

• Hazardous Substances Data: 144060-62-8(Hazardous Substances Data)

Usage

Description

Febuxostat Impurity 8, also known as 3-Descyano-3-formyl Febuxostat, is an impurity found in Febuxostat (F229000), which is a xanthine oxidase/xanthine dehydrogenase inhibitor. It plays a significant role in the pharmaceutical industry due to its association with the active compound used for treating hyperuricemia and chronic gout.

Uses

Used in Pharmaceutical Industry:
Febuxostat Impurity 8 is used as an impurity in the development and manufacturing process of Febuxostat (F229000) for the treatment of hyperuricemia and chronic gout. Its presence is crucial for understanding the purity and effectiveness of the final drug product, ensuring the safety and efficacy of the medication for patients.
Febuxostat Impurity 8 is used as a reference compound for quality control and analytical testing in the pharmaceutical industry. This application is essential for verifying the purity and potency of Febuxostat, ensuring that the drug meets the required standards for therapeutic use.
Additionally, Febuxostat Impurity 8 may be used in research and development for the investigation of its potential effects on the activity of xanthine oxidase/xanthine dehydrogenase, which could lead to the discovery of new therapeutic applications or improvements in the treatment of hyperuricemia and chronic gout.

Upstream product

• 161797-99-5 (2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester) 
• 1380049-41-1 2-(3-formyl-4-hydroxyphenyl)-N,N,4-trimethylthiazole-5-carboxamide 
• 1380049-39-7 2-(4-hydroxyphenyl)-N,N-4-trimethylthiazole-5-carboxamide 
• 1380049-42-2 2-[3-formyl-4-(2-methylpropoxy)phenyl]-N,N-4-trimethylthiazole-5-carboxamide 
• 161798-01-2 ethyl 2‐(3‐formyl‐4‐hydroxyphenyl)‐4‐methylthiazole‐5‐carboxylate 
• 161798-03-4 2-(3-formyl-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 144060-97-9 ethyl 2-(4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate 
• 20524-86-1 dichloromethyl ether 

Downstream Products

• 144060-53-7 febuxostat 
• 161798-03-4 2-(3-formyl-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 1350352-74-7 2-[3-formyl-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid n-butylamine 
• 1350352-73-6 2-[3-formyl-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid methylamine 

Relevant articles and documents

AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF

The present invention relates to process of preparation of 2-(3-cyano-4- isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid (Febuxostat). The present invention in particular relates to an efficient and easily to operate scalable process of manufacturing of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid (Febuxostat) of Formula I and its crystalline polymorphic Form C.

PROCESS FOR THE PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to novel and improved processes for the preparation of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its pharmaceutically acceptable salts thereof. the present invention also provides the novel process for the preparation of crystalline forms of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its intermediates.

2-arylthiazole derivatives and pharmaceutical composition thereof

Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): STR1 wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.